Abstract
The National Cancer Institute of the United States recently announced a major new initiative in understanding the genomes or, more broadly, the molecular phenotypes of exceptional responders. What can we expect to learn from exceptional responders? What are the potential benefits, and how do we approach studying them?
References
Avicenna The Canon of Medicine (Persia, 1025).
Willyard, C. 'Basket studies' will hold intricate data for cancer drug approvals. Nature Med. 19, 655–655 (2013).
Stewart, D. J. & Kurzrock, R. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer 13, 193 (2013).
Chou, A. et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 5, 78 (2013).
Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
Chang, K. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genet. 45, 1113–1120 (2013).
Riley, W. T., Glasgow, R. E., Etheredge, L. & Abernethy, A. P. Rapid, responsive, relevant (R3) research: a call for a rapid learning health research enterprise. Clin. Transl. Med. 2, 10 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Chang, D., Grimmond, S., Evans, T. et al. Mining the genomes of exceptional responders. Nat Rev Cancer 14, 291–292 (2014). https://doi.org/10.1038/nrc3723
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3723
- Springer Nature Limited
This article is cited by
-
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Nature Reviews Cancer (2019)
-
Pancreatic cancer
Nature Reviews Disease Primers (2016)
-
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Nature Reviews Clinical Oncology (2015)
-
Whole genomes redefine the mutational landscape of pancreatic cancer
Nature (2015)